Patients withMYD-88 mutation have shown impressive responses to ibrutinib.Alternatively , brentuximab vedotin (CD30-positive lymphoma),blinatumomab and tafasiamab can be considered34: 91% agreement, and two panelistssuggested palliation for all cases. This evidence concerns the gene TNFRSF8 and lymphoma.